Selected
Type of publications
Regions
Countries
Diseases
Publication date
Target population
Available to download in languages
671 results found
2024
Meningococcal vaccines: WHO position paper on the use of multivalent meningococcal conjugate vaccines in countries of the African meningitis belt, January 2024
  • Position paper
  • Meningococcal disease
Download:
2023 ∙ Eiden, Amanda L. Barratt, Jane Nyaku, Mawuli K.
A review of factors influencing vaccination policies and programs for older adults globally
  • Acceptance
  • Adults
  • Older adults
  • Influenza
  • Pneumococcal disease
  • Herpes zoster
  • Tetanus
Rating:
Not applicable
2023 ∙ Tavabe, Nilay Rezaei Kheiri, Soleiman Dehghani, Mohsen Mohammadian-Hafshejani, Abdollah
A Systematic Review and Meta-Analysis of the Relationship between Receiving the Flu Vaccine with Acute Cerebrovascular Accident and Its Hospitalization in the Elderly
  • Efficacy/effectiveness
  • Older adults
  • Influenza
Rating:
Critically low
2023 ∙ Doggen, Kris van Hoek, Albert Jan Luyten, Jeroen
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
  • Economic aspects
  • Newborn
  • Children
  • Adolescents
  • Adults
  • Pneumococcal disease
  • Rotavirus
  • Human papillomavirus (HPV)
  • Meningococcal disease
  • Mumps
  • Measles
  • Rubella
Rating:
Not applicable
2023 ∙ Nichol, Bethany McCready, Jemma Louise Steen, Mary Unsworth, John Simonetti, Valentina Tomietto, Marco
Barriers and facilitators of vaccine hesitancy for COVID-19, influenza, and pertussis during pregnancy and in mothers of infants under two years: An umbrella review
  • Vaccine/vaccination
  • Acceptance
  • Pregnant women
  • Parents/caregivers
  • COVID-19
  • Influenza
  • Pertussis
Rating:
Not applicable
2023 ∙ Giannelos, Nikolaos Ng, Cheryl Curran, Desmond
Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
  • Economic aspects
  • Adults
  • Older adults
  • Herpes zoster
Rating:
Not applicable
2023 ∙ Jones-Gray, E. Robinson, E. J. Kucharski, A. J. Fox, A. Sullivan, S. G.
Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis
  • Efficacy/effectiveness
  • All age groups
  • Influenza
Rating:
Low
2023 ∙ Conti, A. Broglia, G. Sacchi, C. Risi, F. Barone-Adesi, F. Panella, M.
Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis
  • Efficacy/effectiveness
  • Safety
  • Children
  • Adolescents
  • Adults
  • Meningococcal disease
Rating:
Critically low
2023 ∙ Langer, J. Welch, V. L. Moran, M. M. Cane, A. Lopez, S. M. C. Srivastava, A. Enstone, A. L. Sears, A. Markus, K. J. Heuser, M. Kewley, R. M. Whittle, I. J.
High Clinical Burden of Influenza Disease in Adults Aged
  • Efficacy/effectiveness
  • Older adults
  • Influenza
Rating:
Critically low
2023 ∙ Barbetta, Leticia Mara Dos Santos Correia, Eduardo Thadeu de Oliveira Gismondi, Ronaldo Altenburg Odebrecht Curi Mesquita, Evandro Tinoco
Influenza Vaccination as Prevention Therapy for Stable Coronary Artery Disease and Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials
  • Efficacy/effectiveness
  • Adults
  • Older adults
  • Influenza
Rating:
Critically low